A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site, Mississauga, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HCP inclusion criteria

Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, age above or equal to 18 years at the time of signing informed consent.
Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care

Diagnosed patient inclusion criteria

Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, age above or equal to 18 years at the time of signing informed consent.
Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
Live in one of the countries of interest: United States, Canada, France, Germany, Japan
Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease

At risk patient inclusion criteria

Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
Male or female, age above or equal to 18 years at the time of signing informed consent.
Live in one of the countries of interest: United States, Canada, France, Germany, Japan
Must have one or more risk factors associated with MASH [obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.

Exclusion criteria

Previous participation in this study. Participation is defined as having given informed consent in this study
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Treatment and study plan

No treatment given

Other

No treatment given

Primary outcomes

Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors

Time frame: At the time of survey (Day 1)

Healthcare Provider (HCP) Quantitative Segment 7-point Likert scale

1 indicates very strongly disagree and 7 indicates very strongly agree
Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors

Time frame: At the time of survey (Day 1)

Patient Quantitative Segment 7-point Likert scale

1 indicates very strongly disagree and 7 indicates very strongly agree

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

ACT on MASH: A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

Acronym: MASH

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Oct 1, 2025
Registry last updated: Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed